Analyst Reco. Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
85.49 ^USD	+1.75%		-6.26%	-16.30%

Mar. 11	Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
Mar. 11	Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year	RE

Analyst Reco.

Feb. 17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
Dec. 02	Morgan Stanley Raises Price Target on Guardant Health to $130 From $105, Keeps Overweight Rating	MT
25-10-30	UBS Adjusts Guardant Health Price Target to $110 From $80, Maintains Buy Rating	MT
25-09-29	Guardant Health Says US FDA Approves its Blood Test as Companion Diagnostic for Eli Lilly's Inluriyo	MT
25-09-25	Guardant Health Shares Rise After Wolfe Upgrade	MT
25-09-25	UBS Adjusts Guardant Health Price Target to $80 From $70, Maintains Buy Rating	MT
25-09-25	Wolfe Research Upgrades Guardant Health to Outperform From Peer Perform, Price Target is $75	MT
25-07-30	Guardant Health Q2 revenue beats estimates	RE
25-05-02	Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating	MT
25-05-01	UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating	MT
25-04-14	BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating	MT
25-04-10	Mizuho Initiates Guardant Health at Outperform	MT
25-03-06	Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says	MT
25-03-05	Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating	MT
25-02-21	UBS Adjusts Guardant Health Price Target to $65 From $40, Maintains Buy Rating	MT
25-01-23	Barclays Initiates Guardant Health at Overweight	MT
24-08-26	Nephron Research Downgrades Guardant Health to Sell From Hold, $23 Price Target	MT
24-08-21	UBS Raises Price Target on Guardant Health to $40 From $32, Maintains Buy Rating	MT
24-06-28	Guggenheim Upgrades Guardant Health to Buy From Neutral, Price Target at $36	MT
24-06-04	Canaccord Genuity Adjusts Price Target on Guardant Health to $38 From $30, Maintains Buy Rating	MT
24-06-03	Jefferies Initiates Guardant Health at Buy Rating With $32 Price Target	MT
24-04-29	Canaccord Genuity Adjusts Price Target on Guardant Health to $30 From $45, Maintains Buy Rating	MT
24-04-15	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
24-02-26	Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	MT